Seeking Alpha

Friedman Billings Downgrades MedImmune After Strong Performance

by: TickerSense April 14, 2007 | about: AZN    
About this author:
Friedman Billings downgraded MedImmune, Inc. (MEDI) Friday morning from Outperform to Market Perform. Of all the analysts covering the stock, Friedman Billings has had the best performance over the past year according to Bloomberg's BARR rankings.

click to enlarge
medi

Related Articles
Find People on SA
Financial Advisors | Portfolio Managers Analysts | Traders | VCs | Investor Relations Company Executives
Related Themes:
  1. Drug Manufacturers (38 in last week)
  2. Biotech Diagnosis
  3. Biotech Equipment (1 in last week)
  4. Biotech Research (3 in last week)
More by TickerSense
Other articles by TickerSense »